

## DAFTAR PUSTAKA

- Ananthakrishnan AN, Xavier RJ, Podolsky DK. 2016. Inflammatory bowel disease: pathogenesis. Dalam: Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC, editors (penyunting). Yamada's Textbook of Gastroenterology. Edisi ke-6. United Kingdom: John Wiley & Sons Ltd. hlm. 1364 – 77.
- Ashraf R, Vasiljevic T, Day SL, Smith SC, Donkor ON. 2013. Lactic acid bacteria and probiotic organisms induce different cytokine profile and regulatory T cells mechanisms. *Journal of Functional Foods*. (diunduh 18 Juni 2020). <http://dx.doi.org/10.1016/j.jff.2013.11.006>
- Bang, B. Lichtenberger, LM. 2016. Methods of inducing inflammatory bowel disease in mice. *Curr Protoc Pharmacol*. 72:5.58.1–5.58.42.
- Bernstein CN, Eliakim A, Fedail S, Fried M, Geary R, Goh KL, et al. 2016. World gastroenterology organisation global guidelines inflammatory bowel disease. *J Clin Gastroenterol*. 50(10): 803 – 18.
- Blumberg RS, Snapper SC. 2016. Inflammatory bowel disease: Immunologic considerations & therapeutic implications. Dalam: Greenberger NJ, Blumberg RS, BuRakoff R, editors (penyunting). *Current Diagnosis & Treatment Gastroenterology, Hepatology, & Endoscopy*. Edisi ke-3. New York: Mc Graw-Hill Education. hlm. 14 – 25.
- Campana R, van Hemert S, Baffone W. 2017. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. *Gut Pathog*. 9:1–12.
- Chapot-Chartier M, Kulakauskas S. 2014. Cell wall structure and function in lactic acid bacteria. *Microbial Cell Factories*. 13(Suppl 1): S9.
- Chen X, Zhao X, Wang H, Yang Z, Li J, Suo H. 2017. Prevent effects of *Lactobacillus fermentum* HY01 on dextran sulfate sodium-induced colitis in mice. *Nutrients*. 9, 545.

- Christensen HR, Frøkiær H, dan Pestka JJ. 2002. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. *J Immunol*. 168: 171–8.
- Coqueiro AY, Raizel R, Bonvini A, Tirapegui J, Rogero MM. 2018. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. *International Journal of Food Sciences and Nutrition* (diunduh 14 Juli 2020). Tersedia dari: <http://www.tandfonline.com/loi/ijf20>
- Cross ML, Mortensen RR, Kudsk J, dan Gill HS. 2002. Dietary intake of *Lactobacillus rhamnosus* HN001 enhances production of both Th1 and Th2 cytokines in antigen-primed mice. *Med Microbiol Immunol*. 191: 49–53.
- Cui Y, Wei H, Lu F, Liu X, Liu D, Gu L, et al. 2016. Different effects of three selected *Lactobacillus* strains in dextran sulfate sodium-induced colitis in BALB/c mice. *PLoS ONE*. 11(2): e0148241.
- De Roock S, van Elk M, van Dijk MEA, Timmerman HM, Rijkers GT, Prakken BJ, et al. 2009. Lactic acid bacteria differ in their ability to induce functional regulatory T cells in humans. *Clinical&Experimental Allergy*. 40, 103 – 10.
- Delcenserie V, Martel D, Lamoureux M, Amiot J, Noutin Y, Roy D. 2009. Immunomodulatory effects of probiotics in the intestinal tract. *Curr Issues Mol Biol*. 10: 37–54.
- Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. 2005. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF- $\beta$ -bearing regulatory cells. *J Immunol*. 174: 3237 – 46.
- Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, et al. 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. *World J Gastroenterol*. 13(2): 236 – 43.
- Foligne B, Nutten S, Steidler L, Dennin V, Goudercourt D, Mercenier A, et al. 2006. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: Technical and microbiological aspects. *Digestive Diseases and Sciences*. 51(2): 390 – 400.
- Friedman S, Blumberg RS. 2013. Inflammatory bowel disease. Dalam: Longo DL, Fauci AS, editors (penyunting). *Harrison's Gastroenterology and*

- Hepatology. Edisi ke-2. New York: Mc Graw-Hill Education. hlm. 179 – 203.
- Haller D, Bode C, Hammes WP, Pfeifer AMA, Schiffrin EJ, Blum S. 2000. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. *Gut*. 47: 79–87.
- Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. 2013. A single strain of *Clostridium butyricum* induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. *Cell Host & Microbe*. 13, 711 – 22.
- Hu T, Wang H, Xiang C, Mu J, Zhao X. 2020. Preventive effect of *Lactobacillus acidophilus* XY27 on DSS-induced ulcerative colitis in mice. *Drug Des. Devel. Ther*. 14: 5645–57.
- Jairath V, Feagan BG. 2020. Global burden of inflammatory bowel disease. *Elsevier*. 5, 1 – 2.
- Kangwan N, Kongkarnka S, Boonkerd N, Unban K, Shetty K, Khanongnuch C. 2022. Protective effect of probiotics isolated from traditional fermented tea leaves (miang) from northern Thailand and role of synbiotics in ameliorating experimental ulcerative colitis in mice. *Nutrients*. 14; 227: 1–16.
- Kim MS, Byun JS, Yoon YS, Yum DY, Chung MJ, Lee JC. 2017. A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production. *Beneficial Microbes*. 8(2): 231–41.
- Kurniawati D, Jasaputra DK, Ratnawati H, Tiono H, Sujatno M, Dewi AK, et al. 2010. The comparison effect of Aloe vera L., Psidium guajava Linn, Curcuma domestica Val to colitis ulcerative mice models histopatology. *Jurnal Medika Palanta*. 1(2): 41–8.
- Kwon H, Lee C, So J, Chae C, Hwang J, Sahoo A, et al. 2010. Generation of regulatory dendritic cells and CD4<sup>+</sup>Foxp3<sup>+</sup> T cells by probiotics administration suppresses immune disorders. *PNAS*. 107(5): 2159 – 64.
- La Fata G, Weber P, Mohajeri MH. 2018. Probiotics and the gut immune system : Indirect regulation. *Proniotics & Antimicro Prot*. 10: 11 – 21.

- Lee HS, Han SY, Bae EA, Huh CS, Ahn YT, Lee JH, et al. 2008. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitis in mice. *International Immunopharmacology*. 8, 574 – 80.
- Lee IA, Bae EA, Lee JH, Lee H, Ahn YT, Huh CS, et al. 2010. *Bifidobacterium longum* HY8004 attenuates TNBS-induced colitis by inhibiting lipid peroxidation in mice. *Inflamm Res*. 59: 359 – 68.
- Lukic J, Strahinic I, Jovicic B, Filipic B, Topisirovic L, Kojic M, et al. 2012. Different roles for lactococcal aggregation factor and mucin binding protein in adhesion to gastrointestinal mucosa. *Applied and Environmental Microbiology*. 78(22): 7993 – 8000.
- Liu Z, Liu F, Wang W, Sun C, Gao D, Ma J, et al. 2020. Study of alleviation effects of a combination of *Lactobacillus rhamnosus* and inulin on mice with colitis. *Food Funct*. DOI: 10.1039/C9FO02992C.
- Maassen CBM, van Holten-Meelen C, Balk F, Leer RJ, Laman JD, Boersma WJA, et al. 2000. Strain-dependent induction of cytokine profiles in the gut by orally administered *Lactobacillus* strains. *Vaccine*. 18: 2613–23.
- Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. 2006. Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomized, double blind, placebo controlled GETAID trial. *Gut*. 55: 842–7.
- Masood MI, Qadir MI, Shirazi JH, Khan IU. 2011. *Critical Reviews in Microbiology*. 37(1): 91 – 8.
- Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. 2018. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol*. 53: 305 – 53.
- Minelli EB, Benini A. 2008. Relationship between number of bacteria and their probiotic effects. *Microbial Ecology in Health and Disease*. 20(4): 180–3.
- Neurath MF. 2014. Cytokines in inflammatory bowel disease. *Nature Reviews*. 14: 329 – 42.
- Ng SC, Kaplan GD, Tang W, Banerjee R, Adigopula B, Underwood FE, et al. 2018. Population density and risk of inflammatory bowel disease: A prospective



- population-based study in 13 countries or regions in Asia-Pacific. *Am J Gastroenterol* (diunduh 22 Juni 2020). <https://doi.org/10.1038/s41395-018-0233-2>
- Ng WK, Wong SH, Ng SC. 2016. Changing epidemiological trends of inflammatory bowel disease in Asia. *Intest Res*. 14: 111 – 9.
- Niers LEM, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NOP, Knol EF, et al. 2005. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. *Clin Exp Allergy*. 35: 1481 – 9.
- Park JS, Joe I, Rhee PD, Jeong CS, Jeong G. 2017. A lactic acid bacterium isolated from kimchi ameliorates intestinal inflammation in DSS-induced colitis. *Journal of Microbiology* (diunduh 22 Juli 2020). <http://dx.doi.org/10.1007/s12275-017-6447-y>
- Park JS, Choi JW, Jhun JY, Kwon JY, Lee BI, Yang CW, et al. 2018. *Lactobacillus acidophilus* improves intestinal inflammation in an acute colitis mouse model by regulation of Th17 and Treg cell balance and fibrosis development. *J Med Food*. 00(0): 1–10.
- Paturi G, Phillips M, Jones M, Kailasapathy K. 2007. Immune enhancing effects of *Lactobacillus acidophilus* LAFTI L10 and *Lactobacillus paracasei* LAFTI L26 in mice. *International Journal of Food Microbiology*. 115: 115 – 8.
- Perdigon G, Galdeano CM, Valdez JC, Medici M. 2002. Interaction of lactic acid bacteria with the gut immune system. *European Journal of Clinical Nutrition*. 56(Suppl 4): S21 – S26.
- Perkumpulan Gastroenterologi Indonesia. 2011. Konsensus Nasional Penatalaksanaan IBD di Indonesia. Jakarta.
- Prioult G, Pecquet S, Fliss I. 2004. Stimulation of interleukin-10 production by acidic  $\beta$ -lactoglobulin-derived peptides hydrolyzed with *Lactobacillus paracasei* NCC2461 peptidases. *Clinical and Diagnostic Laboratory Immunology*. 11: 266 – 71.
- Quinto EJ, Jimenez P, Caro I, Tejero J, Mateo J, Girbes T. 2014. Probiotic lactic acid bacteria: A review. *Food and Nutrition Sciences*. 5, 1765 – 75.

- Renes IB, Verburg M, Van Nispen D, Taminiou J, Buller HA, Dekker J, et al. 2002. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. *Int J Colorectal Dis.* 17: 317–26.
- Sengupta P. 2013. The laboratory rat: Relating its age with human's. *Int J Prev Med.* 4, 624 – 30.
- Sharp P, Vilano J. 2012. *The laboratory rat*. Edisi ke-2. New York: CRC Press.
- Smelt MJ, de Haan BJ, Bron PA, van Swam I, Meijerink M, Wells JM, et al. 2013. Probiotics can generate foxp3 T-cell responses in the small intestine and simultaneously inducing CD4 and CD8 T cell activation in the large intestine. *PloS ONE.* 8(7): e68952.
- Sprong RC, Schonewille AJ, van der Meer R. 2010. Dietary cheese whey protein protects rats against mild dextran sulfate sodium-induced colitis: role of mucin and microbiota. *J Dairy Sci.* 93: 1364–71.
- Tanoue T, Atarashi K, Honda K. 2016. Development and maintenance of intestinal regulatory T cells. *Nature Reviews* (diunduh 18 Juni 2020). <http://dx.doi.org/10.1038/nri.2016.36>
- Tsai YT, Cheng P, Pan T. 2012. The immunomodulatory effects of lactic acid bacteria for improving immune functions and benefits. *Appl Microbiol Biotechnol.* 96: 853 – 62.
- Vesterlund S, Karp M, Salminen S, Ouwehand AC. 2006. *Staphylococcus aureus* adheres to human intestinal mucus but can be displaced by certain lactic acid bacteria. *Microbiology.* 152, 1819 – 1826.
- Wang J, Chen H, Yang B, Gu Z, Zhang H, Chen W, Chen YQ. 2016. *Lactobacillus plantarum* ZS2058 produces CLA to ameliorate DSS-induced acute colitis in mice. *RSC Adv.* 6: 14457–64.
- Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, et al. 2013. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. *J Clin Microbiol.* 52(2): 398.

- Wang Y, Liu XP, Zhao ZB, Chen JP, Yu CC. 2011. Expression of CD4<sup>+</sup> forkhead box P3 (FOXP3)<sup>+</sup> regulatory T cells in inflammatory bowel disease. *Journal of Digestive Disease*. 12, 286 – 94.
- Wang Y, Xie Q, Zhang Y, Ma W, Ning K, Xiang JY, et al. 2019. Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microiota, IL-10, and barrier function. *Appl Microbiol Biotechnol* (diunduh 10 Maret 2022). Tersedia dari: <https://doi.org/10.1007/s00253-019-10259-6>
- Wenzel UA, Magnusson MK, Rydstrom A, Jonstrand C, Hengst J, Johansson MEV, et al. 2014. Spontaneous colitis in Muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis. *PLoS ONE*. 9(6): e100217.
- Wong WY, Chan BD, Leung TW, Chen M, dan Tai WC. 2022. Beneficial and anti-inflammatory effects of formulated prebiotics, probiotics, and synbiotics in normal and acute colitis in mice. *J Funct Foods*. 88: 104871. DOI: 10.1016/j.ff.2021.104871.
- Zhang M, Sun K, Wu Y, Yang Y, Tso P, Wu Z. 2017b. Interactions between intestinal microbiota and host immune response in inflammatory bowel disease. *Front Immunol*. 8: 942.
- Zhang M, Zhou L, Zhang S, Yang Y, Xu L, Hua Z, et al. 2017a. *Bifidobacterium longum* affects the methylation level of forkhead box P3 promoter in 2,4,6-trinitrobenzenesulphonic acid induced colitis in rats. *Microbial Pathogenesis*. 110, 426 – 30.
- Zhou L, Liu D, Xie Y, Yao X, Li Y. 2019. *Bifidobacterium infantis* induces protective colonic PD-L1 and Foxp3 regulatory T cells in an acute murine experimental model of inflammatory bowel disease. *Gut Liver*. 13(4): 430–9.